CYTK — CYTOKINETICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1061983 ·
Last close
$51.65
Market Cap
$7.20B
52W High
$88.31
52W Low
$51.38
ADV30
1,951,166
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 47,557,000 | 45,341,000 | -167,088,000 | -190,069,000 | 1,824,780,000 | 203,433,000 | 2,145,951,000 |
| Jun 2026 | 28,624,000 | 23,032,000 | -179,172,000 | -198,762,000 | 1,924,551,000 | 255,271,000 | 2,098,038,000 |
| Mar 2026 | 19,355,000 | 16,803,000 | -183,618,000 | -206,031,000 | 1,273,478,000 | 129,843,000 | 2,100,046,000 |
| Dec 2025 | 17,755,000 | -86,643,000 | -178,366,000 | -183,031,000 | 1,424,537,000 | 122,518,000 | 2,084,162,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-571,969,000
Investing CF
$-364,767,000
Financing CF
$916,132,000
CapEx
$-16,608,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.04
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,081,581,000
Inventory
$807,000
Receivables
$33,889,000
ST Investments
$926,588,000
EBIT TTM
$-640,908,000
Pretax Income TTM
$-777,893,000
Interest Exp TTM
$136,985,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$113,291,000
EBITDA
$-694,489,984
Free Cash Flow
$-397,408,736
Enterprise Value
$7,775,363,072
Total Cash
$1,130,020,992
Total Debt
$1,440,057,984
Shares Out
139,303,351
Trailing EPS
$-6.02
Book Value
$-2.31
ROE
—
ROA
-27.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,039,000 | -612,258,000 | -784,955,000 | 1,424,537,000 | 2,084,162,000 | -659,625,000 | -510,009,000 |
| Dec 2024 | 18,474,000 | -536,248,000 | -589,526,000 | 1,401,673,000 | 1,537,045,000 | -135,372,000 | -395,890,000 |
| Dec 2023 | 7,530,000 | -496,205,000 | -526,244,000 | 824,316,000 | 1,210,639,000 | -386,323,000 | -414,333,000 |
| Dec 2022 | 94,588,000 | -324,202,000 | -388,955,000 | 1,014,775,000 | 1,122,675,000 | -107,900,000 | -299,516,000 |
TTM Snapshot
Revenues TTM
$67,670,000
NetIncome TTM
$-894,002,000
OpCashFlow TTM
—
Assets (Latest)
$1,924,551,000
Forward EPS
$-4.25
Max Pain — expiry 2027-01-15
max pain strike: $40.00 · spot: $51.00 · call oi: 40,768 · put oi: 4,369
Expected Move to 2027-01-15:
±$8.95
(17.55%) —
implied range
$42.05 –
$59.95
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.16B | $82.10 | — |
| AXSM | Axsome Therapeutics, Inc. | $7.15B | $135.95 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $7.36B | $21.12 | — |
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
News headlines (Yahoo Finance, 1h cache)
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
2026-11-17 09:12 · Yahoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-16 21:00 · Yahoo
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
2026-11-16 09:00 · Yahoo
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
2026-11-16 08:12 · Yahoo
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Associ
2026-11-09 12:30 · Yahoo
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
2026-11-09 10:23 · Yahoo
Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
2026-11-05 17:18 · Yahoo
Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript
2026-11-05 17:02 · Yahoo
Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data
2026-11-05 10:11 · Yahoo
How MYQORZO Adoption Will Impact Cytokinetics (CYTK) Stock
2026-11-05 06:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.